Publication date: Jul 18, 2026
Few studies have characterized immune correlates of SARS-CoV-2 infection risk in children, particularly those with hybrid immunity from vaccination and prior infection. We conduct a prospective community-based cohort study of 1509 U. S. children (2022-2024), performing weekly SARS-CoV-2 PCR testing and measuring baseline binding and neutralizing antibody titers against multiple variants. Higher antibody levels, notably nucleocapsid-binding and Omicron-specific neutralizing antibodies, are significantly associated with reduced risk of SARS-CoV-2 infection after adjusting for age, recent infection, exposure settings, and temporal trends (adjusted hazard ratios ranging from 0. 60 to 0. 87 per positive unit difference in log-fold antibody level (AU/mL)). Secondary analyses suggest these findings are robust to multiple stratifications of SARS-CoV-2 immune status, are relevant across different pediatric age groups, and appear to apply to both overall and symptomatic infection risk. Together, the results suggest that specific antibodies can predict relative infection risk in pediatric populations with diverse immune histories. Understanding these immune correlates may inform tailored vaccination strategies and risk assessments as SARS-CoV-2 continues to evolve.
Open Access PDF
| Concepts | Keywords |
|---|---|
| Antibody | |
| Based | |
| Binding | |
| Children | |
| Cohort | |
| Community | |
| Correlates | |
| Cov | |
| Immune | |
| Infection | |
| Neutralizing | |
| Prospective | |
| Risk | |
| Sars | |
| Vaccination |
Semantics
| Type | Source | Name |
|---|---|---|
| disease | MESH | SARS-CoV-2 infection |
| pathway | REACTOME | SARS-CoV-2 Infection |
| disease | MESH | infection |
| pathway | REACTOME | Reproduction |
| disease | MESH | included |
| disease | MESH | Infectious Diseases |
| disease | MESH | asymptomatic infections |
| disease | MESH | strain |
| drug | DRUGBANK | Angiotensin II |
| disease | MESH | re infection |
| drug | DRUGBANK | Coenzyme M |
| drug | DRUGBANK | Methionine |
| disease | MESH | MSD |
| disease | MESH | fever |
| disease | MESH | chills |
| disease | MESH | cough |
| disease | MESH | fatigue |
| disease | MESH | aches |
| disease | MESH | headache |
| disease | MESH | sore throat |
| disease | MESH | runny nose |
| disease | MESH | nausea |
| disease | MESH | vomiting |
| disease | MESH | diarrhea |
| disease | MESH | chest pain |
| disease | MESH | plan |
| disease | MESH | Dis |
| disease | MESH | influenza |
| disease | MESH | breakthrough infection |
| drug | DRUGBANK | Carboxyamidotriazole |
| disease | MESH | Severe acute respiratory syndrome |
| pathway | REACTOME | Immune System |
| disease | MESH | David |
| disease | MESH | Ash |
| drug | DRUGBANK | Porphobilinogen |
| disease | MESH | CML |
| disease | MESH | CMM |
| disease | MESH | LMS |